RedHill Unveils Plans For Pivotal Phase III Study For Crohn’s Therapy
Executive Summary
RedHill Biopharma’s study results for its novel antibiotic approach to Crohn’s disease has left the company with some unanswered questions, despite hitting its endpoints in a recent Phase III study. Its COO, Gilead Raday, talks to Scrip about the next steps for the study.